药学前沿大讲堂第520讲—— mRNA疫苗背后的科学

报告人简介:

       沈栋博士是美国华人生物医药科技协会第20任会长，上海交通大学医学院临床医疗系毕业，美国约翰霍普金斯大学医学院博士毕业，博士导师是世界肿瘤权威Bert Vogelstein院士。沈栋博士在校期间担任约翰霍普金斯大学学生会主席，是2007年国家优秀留学生奖获得者，是阿斯利康公司华人科学家协会创办人，是美国强生集团2017年创新奖和2018年领袖奖获得者，是美国RNAImmune(达冕生物)公司创始人和总裁，聚焦信使核糖核酸(mRNA)，打造拥有自主知识产权的mRNA信使核糖核酸人工智能技术迭代平台，传染病预防性疫苗，癌症治疗疫苗和新一代冠状病毒信使核糖核酸疫苗。沈栋博士所有文章都发表在Nature,Science,Cell,New England Meddicine,Nature Genetics,JAMA等国际顶级期刊。目前沈栋博士的文章被国际同行引用已经超过20000次。

报告内容简介：

      mRNA vaccines are a new type of vaccine to protect against infectious diseases. To trigger an immune response, many vaccines put a weakened or inactivated germ into our bodies. Not mRNA vaccines. Instead, they teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies. That immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies. Researchers have been studying and working with mRNA vaccines for decades. Interest has grown in these vaccines because they can be developed in a laboratory using readily available materials. This means the process can be standardized and scaled up, making vaccine development faster than traditional methods of making vaccines. mRNA vaccines have been studied before for flu, Zika, rabies, and cytomegalovirus (CMV). As soon as the necessary information about the virus that causes COVID-19 was available, scientists began designing the mRNA instructions for cells to build the unique spike protein into an mRNA vaccine. Future mRNA vaccine technology may allow for one vaccine to provide protection for multiple diseases, thus decreasing the number of shots needed for protection against common vaccine-preventable diseases. Beyond vaccines, cancer research has used mRNA to trigger the immune system to target specific cancer cells.